Esto lo convierte en un sujeto de estudio principal para la bioingeniera de tejidos y la investigacin de la matriz extracelular
Therefore, if the deficiency poses a 'vital' risk, intravenous administration is appropriate, but if the goal is to supplement or prevent a deficiency, oral administration works, as shown by analysis
Interestingly, gemcitabine has already been proposed as an adjuvant in combination with another MEKi, trametinib, in adenocarcinoma treatment, but due to low efficacy, the studies were terminated [70]
This may be due to the vicious cycle of increased lipid peroxidation and free radicals in cancer cells, while the decrease in GPx activity makes cancer tissues more susceptible to the damaging effects of free radicals